Biolase (BIOL)

Data from SEC filings
Employee count
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
The following are the results of the voting on the proposals submitted to stockholders at the Annual Meeting held on April 28, 2022.
Proposal 1 – Stockholders elected each of the Company’s seven nominees for director, as set forth below:

Nominee For Against Abstain Broker Non-
John R. Beaver31,477,2775,454,1302,054,77840,176,443
Jonathan T. Lord, M.D.31,716,1325,144,3032,125,75040,176,443
Kathleen T. O’Loughlin, D.D.S.32,248,0074,658,0052,080,17340,176,443
Jess Roper32,042,1324,556,9032,387,15040,176,443
Martha Somerman, D.D.S.32,171,6134,696,9882,117,58440,176,443
Carol Gomez Summerhays, D.D.S.32,157,0644,726,3662,102,75540,176,443
Kenneth P. Yale, D.D.S., J.D.32,646,1404,228,5872,111,45840,176,443
Proposal 2 – Stockholders voted, on an advisory basis, to approve the compensation of the Company’s named executive officers, as set forth below:

ForAgainstAbstainBroker Non-Votes
Proposal 3 – Stockholders voted to approve the adoption of an amendment to the Certificate of Incorporation to effect a reverse stock split of Company common stock (without reducing the authorized number of shares of Company common stock), if and when determined by the Company’s Board of Directors:

ForAgainstAbstainBroker Non-Votes

Proposal 4 – Stockholders ratified the appointment of BDO USA, LLC as the Company’s independent registered public accounting firm for the year ending December 31, 2022, as set forth below:

ForAgainstAbstainBroker Non-Votes